Tevogen Advances AI Initiative with PredicTcell™

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 27 2026

0mins

TVGN-5.08%

Should l Buy TVGN?

Source: Newsfilter

Algorithm Training Progress: Tevogen.AI's PredicTcell™ training algorithm is nearing completion, having been trained on one of the industry's largest peptide datasets with feature expansion exceeding 180 parameters, resulting in an approximate 10% improvement in precision, which will significantly enhance target identification efficiency in drug development.
Exploring Commercial Partnerships: The company has begun evaluating potential co-development partnerships to support broader applications of the PredicTcell™ platform, aiming to reduce development timelines and costs through advanced predictive modeling, thereby improving overall experimental efficiency.
Internal Application Development: Tevogen.AI has developed an internal application and portal designed to provide a scalable and user-friendly environment for the PredicTcell™ model, which will optimize internal workflows and lay the groundwork for a future customer-facing platform.
Clear Strategic Goals: Chief Information Officer Mittul Mehta stated that advancing PredicTcell™ toward completion marks an important milestone in the AI strategy, with a future focus on maintaining scientific rigor and building scalable tools to extend the platform's impact.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy TVGN?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on TVGN

About TVGN

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Tevogen Bio's AI Model Approaches Completion for Commercial Use

Apr 28 2026NASDAQ.COM

AI Model Progress: Tevogen Bio's PredicTcell model is nearing the end of its training phase, marking a crucial step towards future commercial deployment, which is expected to significantly enhance drug discovery efficiency.
Dataset Advantage: The model has been trained on one of the industry's largest curated peptide datasets, incorporating over 180 features in its latest version, with internal assessments indicating a 10% improvement in precision, thereby providing greater confidence in drug development.
Co-Development Exploration: As the model approaches completion, Tevogen is evaluating potential co-development partnerships to broaden the platform's applications, aiming to address the significant challenge of identifying high-confidence biological targets in drug development.
Internal Application Development: Tevogen.AI has built an initial internal application and portal for the PredicTcell model, designed to streamline internal workflows and potentially serve as the foundation for a future customer-facing platform.